{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:31:10Z","timestamp":1770910270536,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1714,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1111\/j.1742-1241.2010.02598.x","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T15:29:20Z","timestamp":1293031760000},"page":"5-7","source":"Crossref","is-referenced-by-count":15,"special_numbering":"supplement s169","title":["Clinical perspective: biomarkers in pulmonary arterial hypertension"],"prefix":"10.1155","volume":"65","author":[{"given":"G. A.","family":"Heresi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definition Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1378\/chest.130.4.1198","article-title":"The current treatment of pulmonary arterial hypertension: time to redefine success","volume":"130","author":"Rich","year":"2006","journal-title":"Chest"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ahj.2007.02.037","article-title":"A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology","volume":"153","author":"Macchia","year":"2007","journal-title":"Am Heart J"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1742-1241.2009.02117.x","article-title":"Biomarkers in pulmonary arterial hypertension","volume":"162","author":"Rafeq","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High n-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of n-terminal brain natriuretic peptide (n-tprobnp) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200308-1142OC","article-title":"Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension","volume":"170","author":"Leuchte","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3899\/jrheum.090997","article-title":"Comparison of brain natriuretic peptide (bnp) and nt-probnp in screening for pulmonary arterial hypertension in patients with systemic sclerosis","volume":"37","author":"Cavagna","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers), endorsed by the international society of heart and lung transplantation (ishlt)","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (reveal)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","article-title":"Serum n-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension","volume":"129","author":"Fijalkowska","year":"2006","journal-title":"Chest"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1183\/09031936.00074309","article-title":"Disproportionate elevation of n-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension","volume":"35","author":"Mathai","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00408-010-9232-9","article-title":"Cxc-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival","volume":"188","author":"Heresi","year":"2010","journal-title":"Lung"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB15|cit15","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1164\/rccm.200608-1189OC","article-title":"Absence of t cells confers increased pulmonary arterial hypertension and vascular remodeling","volume":"175","author":"Taraseviciene-Stewart","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","article-title":"C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension","volume":"53","author":"Quarck","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.201001-0007OC","article-title":"Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension","volume":"182","author":"Heresi","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/rccm.200802-235OC","article-title":"Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension","volume":"178","author":"Nickel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1253\/circj.CJ-10-0270","article-title":"Identification of new prognostic factors of pulmonary hypertension","volume":"74","author":"Miura","year":"2010","journal-title":"Circ J"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (aries) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Eng J Med"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.0006-341X.2004.00222.x","article-title":"Prentice\u2019s approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints","volume":"60","author":"Alonso","year":"2004","journal-title":"Biometrics"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1541-0420.2006.00538.x","article-title":"Quantification of the prentice criteria for surrogate endpoints","volume":"62","author":"O\u2019Quigley","year":"2006","journal-title":"Biometrics"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1378\/chest.07-0275","article-title":"Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil","volume":"135","author":"Gilbert","year":"2009","journal-title":"Chest"},{"key":"10.1111\/j.1742-1241.2010.02598.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"Bnp-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (time-chf) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"JAMA"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2010.02598.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2010.02598.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:08:12Z","timestamp":1643332092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2010.02598.x"}},"subtitle":["Pulmonary Hypertension Reviews: Perspective"],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02598.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}